<span item_type="fundamental" item_id="cbbdc4fdc9dc0434997b54419b4b4c23" counter_id="ST/US/RGBP" env="prod"></span><span item_type="announcement" item_id="521071739324079873" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 59.07 K.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $59,065 for the three months ended March 31, 2025, and $59,064 for the same period in 2024. Revenue from related parties was $27,425 for both periods, and $31,640 was recognized from licenses granted to Oncology Pharma, Inc. for both periods.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Expenses</strong>: $172,414 for the three months ended March 31, 2025, compared to $160,135 for the same period in 2024. The primary expenses in 2025 were $136,566 in consulting and professional fees and $22,500 in rent.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li><li><strong>Net Loss</strong>: $19,354 for the three months ended March 31, 2025, compared to $122,454 for the same period in 2024. The decrease in net loss is primarily due to a derivative gain of $128,963 recognized in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $167,609 for the six months ended March 31, 2025, compared to - $371,658 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $168,655 for the six months ended March 31, 2025, primarily from proceeds from notes payable.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Derivative Liability</strong>: Increased to $1,691,143 as of March 31, 2025, from $1,404,090 as of September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue incurring significant research and development costs for product development and professional costs to remain publicly traded. The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li><li><strong>Liquidity &amp; Capital Resources Outlook</strong>: As of March 31, 2025, the company had cash of $1,761 and a net working capital deficit of - $5,716,131. The company has incurred recurring losses and requires significant cash resources to execute its business plans.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225012619/form10-q.htm"></span></li></ul>

Regen BioPharma, Inc. | 10-Q: FY2025 Q2 Revenue: USD 59.07 K